...
rvnc-img

Revance The, Common Stock

RVNC

NMQ

$3.09

+$0.02

(0.65%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$320.48M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
3.34M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.95
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.3 L
$9.74 H
$3.09

About Revance The, Common Stock

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameRVNCSectorS&P500
1-Week Return0.32%-2.12%-3%
1-Month Return-18.68%-3.42%-0.73%
3-Month Return-46.82%-11.13%2.87%
6-Month Return7.67%-5.74%7.17%
1-Year Return-59.23%3.97%25.31%
3-Year Return-81.51%1.05%28.38%
5-Year Return-80.96%34.37%81.89%
10-Year Return-82.49%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue413.00K15.32M77.80M132.56M234.04M[{"date":"2019-12-31","value":0.18,"profit":true},{"date":"2020-12-31","value":6.55,"profit":true},{"date":"2021-12-31","value":33.24,"profit":true},{"date":"2022-12-31","value":56.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue102.86M4.77M23.41M51.67M152.16M[{"date":"2019-12-31","value":67.6,"profit":true},{"date":"2020-12-31","value":3.13,"profit":true},{"date":"2021-12-31","value":15.38,"profit":true},{"date":"2022-12-31","value":33.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(102.45M)10.56M54.39M80.90M81.88M[{"date":"2019-12-31","value":-125.12,"profit":false},{"date":"2020-12-31","value":12.89,"profit":true},{"date":"2021-12-31","value":66.43,"profit":true},{"date":"2022-12-31","value":98.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(24805.81%)68.88%69.91%61.03%34.98%[{"date":"2019-12-31","value":-35482.87,"profit":false},{"date":"2020-12-31","value":98.53,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":87.29,"profit":true},{"date":"2023-12-31","value":50.04,"profit":true}]
Operating Expenses164.87M283.72M329.06M353.07M398.65M[{"date":"2019-12-31","value":41.36,"profit":true},{"date":"2020-12-31","value":71.17,"profit":true},{"date":"2021-12-31","value":82.54,"profit":true},{"date":"2022-12-31","value":88.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(164.46M)(273.16M)(274.68M)(272.17M)(316.78M)[{"date":"2019-12-31","value":-16445900000,"profit":false},{"date":"2020-12-31","value":-27316200000,"profit":false},{"date":"2021-12-31","value":-27467600000,"profit":false},{"date":"2022-12-31","value":-27216900000,"profit":false},{"date":"2023-12-31","value":-31677700000,"profit":false}]
Total Non-Operating Income/Expense10.56M(22.37M)(12.57M)(25.35M)(11.74M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-211.83,"profit":false},{"date":"2021-12-31","value":-119.01,"profit":false},{"date":"2022-12-31","value":-239.98,"profit":false},{"date":"2023-12-31","value":-111.12,"profit":false}]
Pre-Tax Income(159.43M)(284.71M)(281.31M)(355.72M)(323.69M)[{"date":"2019-12-31","value":-15942900000,"profit":false},{"date":"2020-12-31","value":-28470900000,"profit":false},{"date":"2021-12-31","value":-28131000000,"profit":false},{"date":"2022-12-31","value":-35572200000,"profit":false},{"date":"2023-12-31","value":-32368600000,"profit":false}]
Income Taxes(3.21M)(2.62M)5.51M700.00K300.00K[{"date":"2019-12-31","value":-58.25,"profit":false},{"date":"2020-12-31","value":-47.52,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":12.69,"profit":true},{"date":"2023-12-31","value":5.44,"profit":true}]
Income After Taxes(156.22M)(282.09M)(286.82M)(356.42M)(323.99M)[{"date":"2019-12-31","value":-15621700000,"profit":false},{"date":"2020-12-31","value":-28208900000,"profit":false},{"date":"2021-12-31","value":-28682400000,"profit":false},{"date":"2022-12-31","value":-35642200000,"profit":false},{"date":"2023-12-31","value":-32398600000,"profit":false}]
Income From Continuous Operations(159.43M)(282.09M)(281.31M)(356.42M)(414.24M)[{"date":"2019-12-31","value":-15942900000,"profit":false},{"date":"2020-12-31","value":-28208900000,"profit":false},{"date":"2021-12-31","value":-28131000000,"profit":false},{"date":"2022-12-31","value":-35642200000,"profit":false},{"date":"2023-12-31","value":-41423900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(156.22M)(282.09M)(286.82M)(356.42M)(323.99M)[{"date":"2019-12-31","value":-15621700000,"profit":false},{"date":"2020-12-31","value":-28208900000,"profit":false},{"date":"2021-12-31","value":-28682400000,"profit":false},{"date":"2022-12-31","value":-35642200000,"profit":false},{"date":"2023-12-31","value":-32398600000,"profit":false}]
EPS (Diluted)(3.66)(4.83)(4.18)(3.94)(3.79)[{"date":"2019-12-31","value":-366,"profit":false},{"date":"2020-12-31","value":-483,"profit":false},{"date":"2021-12-31","value":-418,"profit":false},{"date":"2022-12-31","value":-394,"profit":false},{"date":"2023-12-31","value":-379,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RVNC
Cash Ratio 2.30
Current Ratio 4.12
Quick Ratio 3.05

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RVNC
ROA (LTM) -24.36%
ROE (LTM) -2096.78%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RVNC
Debt Ratio Lower is generally better. Negative is bad. 1.35
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.35

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RVNC
Trailing PE NM
Forward PE NM
P/S (TTM) 1.26
P/B 12.30
Price/FCF NM
EV/R 2.42
EV/Ebitda NM
PEG NM

FAQs

What is Revance The share price today?

Revance The (RVNC) share price today is $3.09

Can Indians buy Revance The shares?

Yes, Indians can buy shares of Revance The (RVNC) on Vested. To buy Revance The from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RVNC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Revance The be purchased?

Yes, you can purchase fractional shares of Revance The (RVNC) via the Vested app. You can start investing in Revance The (RVNC) with a minimum investment of $1.

How to invest in Revance The shares from India?

You can invest in shares of Revance The (RVNC) via Vested in three simple steps:

  • Click on Sign Up or Invest in RVNC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Revance The shares
What is Revance The 52-week high and low stock price?

The 52-week high price of Revance The (RVNC) is $9.74. The 52-week low price of Revance The (RVNC) is $2.3.

What is Revance The price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Revance The (RVNC) is

What is Revance The price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Revance The (RVNC) is 12.30

What is Revance The dividend yield?

The dividend yield of Revance The (RVNC) is 0.00%

What is the Market Cap of Revance The?

The market capitalization of Revance The (RVNC) is $320.48M

What is Revance The’s stock symbol?

The stock symbol (or ticker) of Revance The is RVNC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top